352359-22-9 Usage
Uses
Used in Organic Synthesis:
1-(TERT-BUTOXYCARBONYL)-6-CHLORO-1H-INDOL-2-YLBORONIC ACID is used as a reagent for the formation of carbon-carbon and carbon-heteroatom bonds in organic synthesis. Its boronic acid functional group facilitates the formation of these bonds, making it a valuable component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(TERT-BUTOXYCARBONYL)-6-CHLORO-1H-INDOL-2-YLBORONIC ACID is used as a building block for the synthesis of biologically active compounds. The presence of the chloro and indole groups allows for the development of pharmaceuticals with potential therapeutic applications.
Used in Pharmaceutical Industry:
1-(TERT-BUTOXYCARBONYL)-6-CHLORO-1H-INDOL-2-YLBORONIC ACID is used as a key intermediate in the synthesis of pharmaceuticals. Its unique structure and functional groups contribute to the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
1-(TERT-BUTOXYCARBONYL)-6-CHLORO-1H-INDOL-2-YLBORONIC ACID is also used as a precursor in the synthesis of agrochemicals. Its potential to form biologically active compounds makes it a valuable asset in the development of new pesticides and other agricultural chemicals.
Used in Research and Development:
1-(TERT-BUTOXYCARBONYL)-6-CHLORO-1H-INDOL-2-YLBORONIC ACID is utilized in research and development for the preparation of complex molecules. Its versatility in forming various types of bonds and its compatibility with a range of chemical reactions make it an essential tool in the exploration of new chemical entities and their potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 352359-22-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,2,3,5 and 9 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 352359-22:
(8*3)+(7*5)+(6*2)+(5*3)+(4*5)+(3*9)+(2*2)+(1*2)=139
139 % 10 = 9
So 352359-22-9 is a valid CAS Registry Number.
InChI:InChI=1/C13H15BClNO4/c1-13(2,3)20-12(17)16-10-7-9(15)5-4-8(10)6-11(16)14(18)19/h4-7,18-19H,1-3H3
352359-22-9Relevant academic research and scientific papers
A kind of aldosterone synthase modulators method for the preparation of intermediates
-
, (2017/02/28)
The invention discloses a method for preparing an aldosterone synthase conditioning agent intermediate. The method comprises the following steps: implementing reaction on a reaction substrate under Boc protection with hydrogen chloride and ethanol for acetal protection, directly heating to remove Boc protection without separation, implementing N-methylation reaction so as to obtain an N-methylation product, and directly removing acetal protection without separation, thereby obtaining a target product. The method is high in route reaction conversion rate and high in product purity, the product quality can be effectively ensured, and workshop production can be achieved.
PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS
-
Page/Page column 149-150, (2008/06/13)
The present invention relates to compounds of the general formula (I) wherein X, Y, Z, A, Ar, R1, R2, R3, and R4 are as defined herein, which compounds are inhibitors of MNK2 and MNK1. The invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising the compounds, and the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of disorders related to undesired activity of MNK1 and/or MNK2 kinases.
2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
-
Page/Page column 77, (2008/06/13)
The present invention is directed to a compound of Formula (XVI) wherein R, R2, R3, R4, R5, R6, R7 and n are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmac
SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
-
Page/Page column 34, (2008/06/13)
The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes
